Earnings Highlights
EPS Actual
0.05
EPS Estimate
-0.54
Revenue Actual
Revenue Estimate
***
behavioral analysis Our platform focuses on delivering stock insights based on earnings, valuation, and market activity. Protagonist Therapeutics Inc. (PTGX) reported first-quarter 2026 earnings per share (EPS) of $0.05, well above the consensus estimate of -$0.5435, representing a surprise of 109.2%. The company recorded no revenue for the quarter, consistent with its pre-commercial stage. Despite the significant EPS beat, the stock declined by 0.69% as investors likely weighed the lack of near-term revenue catalysts.